ADPT
NASDAQAdaptive Biotechnologies Corporation
Price$15.80+1.00 (+6.77%)
01:30 PM07:00 PM
News · 26 weeks79-64%
2025-12-072026-05-31
Mix5090d
- Insider39(78%)
- SEC Filings5(10%)
- Other4(8%)
- Earnings2(4%)
Latest news
25 items- PRAt ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and ResearchSEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO a
- PRAdaptive Biotechnologies to Participate in Upcoming Investor ConferencesSEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MNHosting 1x1 meetings on Thursday, May 28thWilliam Blair 46th Annual Growth Stock Conference – Chicago, ILPresentation on Wednesday, June 3rd at 3:20 p.m. Central Time Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conf
- INSIDERChief Financial Officer Piskel Kyle sold $40,620 worth of shares (3,115 units at $13.04), decreasing direct ownership by 1% to 256,725 units (SEC Form 4) to satisfy tax liability4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adaptive Biotechnologies CorporationSCHEDULE 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)
- SECSEC Form 10-Q filed by Adaptive Biotechnologies Corporation10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)
- SECAdaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
- PRAdaptive Biotechnologies Reports First Quarter 2026 Financial ResultsSEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. "We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performance reinforces our market leadership position and the differentiated value of our platform," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "With disciplined e
- INSIDERPresident and COO Rubinstein Julie sold $270,897 worth of shares (19,037 units at $14.23) as part of a pre-agreed trading plan and exercised 14,707 shares at a strike of $8.46, decreasing direct ownership by 1% to 377,802 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERPresident and COO Rubinstein Julie exercised 44,166 shares at a strike of $8.46 and sold $798,423 worth of shares (57,180 units at $13.96) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 382,132 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECSEC Form DEFA14A filed by Adaptive Biotechnologies CorporationDEFA14A - Adaptive Biotechnologies Corp (0001478320) (Filer)
- SECSEC Form DEF 14A filed by Adaptive Biotechnologies CorporationDEF 14A - Adaptive Biotechnologies Corp (0001478320) (Filer)
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours a
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Lo Francis4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Robins Harlan S4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Robins Chad M4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adaptive Biotechnologies CorporationSCHEDULE 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Rubinstein Julie4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
ADPT FAQ
7 questionsWhat does Adaptive Biotechnologies Corporation do?
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and...Where does ADPT stock trade?
Adaptive Biotechnologies Corporation (ADPT) is listed on NASDAQ.What sector and industry is ADPT in?
Adaptive Biotechnologies Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Adaptive Biotechnologies Corporation go public?
Adaptive Biotechnologies Corporation (ADPT) completed its IPO in 2019.What are analysts saying about ADPT?
Adaptive Biotechnologies Corporation has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $2100.00 price target on 2025-12-02. Recent price targets range from $800.00 to $2100.00.What companies are similar to ADPT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ADPT side-by-side with any of them on Quantisnow.How can I track ADPT on Quantisnow?
Quantisnow aggregates Adaptive Biotechnologies Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADPT to receive live email and push alerts on every new disclosure.